We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Urinary Antigen Assay Detects Legionella

By LabMedica International staff writers
Posted on 16 Feb 2012
An antigen test had been evaluated for its ability to diagnose Legionnaires’ disease (LD) using urine samples. More...


Laboratory diagnosis of Legionella pneumophila infections in patients with pneumonia is based on culture, serological testing, molecular testing, and detection of soluble L. pneumophila antigen in urine.

Scientists at the Regional Laboratory of Public Health (Haarlem, The Netherlands) tested frozen urine samples from a well-described sample of patients with and without LD. Urine samples were collected between 1997 and 2010 and were stored at -70 °C until processing was performed. These included 58 urine samples from 58 patients with LD. The specificity of the test was determined by using urine samples collected from 38 patients with respiratory tract infections other than Legionella infections.

The SD Bioline Legionella Urinary Antigen test (Standard Diagnostics Inc., Kyonggi-do, Korea) was compared with those obtained by the BinaxNOW Legionella Urinary Antigen enzyme immunoassay (EIA) (Galway, Ireland). A total of 96 samples were tested with the SD Bioline and BinaxNOW test. SD Bioline test was positive for 46/58 samples with sensitivity of the assay estimated as 79%. The BinaxNOW urinary antigen test was positive 47/58, with a sensitivity of 81%. These results were obtained after 15 minutes of incubation. The difference in sensitivity between SD Bioline test and BinaxNOW is comparable. Both tests were negative in the 38 samples from the non-Legionella patients giving a specificity of 100% for both assays.

LD is an acute pneumonia caused by Legionella species, which are non-spore-forming Gram-negative rods. L. pneumophila serogroup 1 accounts for more than 90% of human infections and is the most important etiological agent of LD. It is estimated that 8,000-18,000 cases of Legionnaires' disease occur in the USA each year. The authors concluded that the findings of the evaluation indicate that the SD Bioline test is both sensitive and specific and could be a good alternative for the detection of L. pneumophila serogroup 1 antigen in urine from patients suspected of having LD. The study was published in the January 2012 edition of the Journal of Infection.

Related Links:
Regional Laboratory of Public Health
Standard Diagnostics Inc.
BinaxNOW


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.